Member Info for AquaeSulis01

Will be interesting to see the short term impact on the sp following this announcement, huge upside potential and very little if any downside risk now and the current sp still takes no account of the value of the Dermatonics acquisition

Croda does not have a seat on the Board, Dr Surinder Chahal has retired from Croda and is now a freelance Consultant so not under the thumb at all. Regarding a Croda bid, i suspect they will wait to gauge the uptake for the skinbiotix ingredient before weighing up a bid for the company or at least the Cosmetics pillar of the Company

It is bel. On the downside there were no forward sales to VIPs as some have predicted and hence the money from royalties wont roll in until mid 2025 but fortunately SA mitigated the risk to short term finances by doing the discounted placing to new sticky hands investors meaning no further fund raises to keep the lights on will be needed again. Happy days and TW will now stop talking about if Croda happens as it is now a when with the main launch clearly dated in Apr 25

Welcome back bel, let's hope it funds a good few cruises for you

It's not to do with the financial side, it is more about ensuring the social risks etc (think relocation plans and actions covered in the minor works) are properly addressed, which we have been assured have been, hence confidence in sign-off following the site visit.

"Our development impact framework

AFC’s DI Framework provides a systematic approach to measure and understand how our investments in Africa support sustainable economic growth, social prosperity and industrialisation. It builds on our definition of sustainability which comprises six key pillars: environmental and social risks, occupational health and safety, economic development, social inclusion, climate finance, and corporate social responsibility.

To ensure that DI is always considered, we have integrated the framework into our investment process at multiple stages including deal screening, due diligence, deal approval, monitoring and reporting. We also leverage on the Joint Impact Model, a web-based tool for impact-oriented investors – developed jointly by Development Finance Institutions and Multilateral Development Banks (CDC, FMO, BIO, Proparco, AfDB and FinDev Canada) in collaboration with Steward Requeen to measure DI across our portfolio."

https://www.africafc.org/our-impact/our-approach-to-impact

The RNS https://www.lse.co.uk/rns/OPTI/sweetbiotix174-overview-85x5yeldiax4jjf.html

I find it odd that you expect a company to make available to its investors a lab scale product in advance of its commercial scaled up launch. First of all there are several different sweetbiotix products for use in different applications or as a standalone sugar substitute and now that scale-up has been achieved for a number of those products we have been told to expect releases this calendar year; it either happens in which case happy days or SOH misses another promised deadline and you can rightly return 01st Jan 2025 and pan the company on its latest failure but in the interim I would suggest you let everyone Enjoy the Silence rather than suffer the silence

So you believe the US Partner has been paying an annual 100k dollar pre launch fee for a phantom product?

How many new customers have been brought in by Steen? Revenue growth almost entirely down to existing Customer Seed Health growing their Business, in fact UK revenue has halved since 2023. SOH will act as Interim CEO if necessary saving the near £300K salary and pension contributions awarded to Steen

From those excluded from taking part in the Study they ought to add LTH's in Opti, PBX and SBTX on the basis the stress is self induced and will go away if the share prices ever recover to former levels!

Good job you didn't focus on the India sales for 2023 mol which despite this upbeat message in the Sep 2023 half year report "· Improved sales performance in H1 2023 by Apollo Pharmacies (up 500%) in India and Nahdi Medical (up 30%) in Saudi Arabia following more active account management. These increased sales are not reflected in H1 but impact on restocking requirements in H2 2023" resulted in EOY sales revenue of precisely zero

Anyone wondering why AFC has insisted on Minor Works Completion prior to final sign-off should realise this is normal process for what they classify as Class A Risk Projects. Process (which includes mandatory site visits) leading too final sign-off at link below

https://www.afdb.org/sites/default/files/documents/environmental-and-social-assessments/afc-environmental-and-social-risk-management-procedure-manual_2020_0.pdf

Dobbin, it was my mistake that led to the confusion, sweetbiotix is priced in kgs. One question I do have though is as the original aim of the US Partner was to optimise scale up to a point where the sweetbiotix could be profitable within a 10% price difference with sugar how much granulated sweetbiotix will be included in a 1 kg bag of sugar equivalent as opposed to a bulking agent as the pricing suggest approx 1/10th?

Hi direcons, the reason I confused the prices is because SOH originally suggested using the slimbiome price as a guideline which was priced in tonnes albeit £30,000 per metric tonne which of course = £30 per kg. Have to wonder why SOH has therefore elected to use kg rather than tonnes for sweetbiotix given the large Firmenich forecasts and it may well be that the initial soft launch will be more realistically tracked in kgs until regulatory clearances and mass adoption by major B2B Customers kick in which may be 3 years down the line, hence the subdued sp reaction. That said any confirmed sweetbiotix launch will start to permanently ramp up the sp from here.

Hi Direcons, no it's me going senile reading things that aren't there

Dire that unit of measurement was incorrect and rectified to tonne in the recent update on 20th Aug

The products have cleared all regulatory requirements for food supplements, it was a pre-launch requirement "AxisBiotix will be seeking regulatory approval for the product as a food supplement in parallel in the UK, US and Europe, with the intention to launch within these regions post the respective approvals." so yes could be sold in Walmart etc and hence the impending Amazon US listing

Yes should read per tonne as shown in the RNS else we would be looking at revenue in the £Bs which would be nice :)

The problem SOH has in providing more specific milestone based forecasts is that there are 12 patents for different sweetbiotix some of which will almost certainly require separate GRAS approval before they can be launched and some likely can be launched without formal GRAS approval, hence the phased and soft launch introduction. What we have been informed is that once all sweetbiotix variants are approved and good to go annual demand from just one partner is likely over 100,000 metric tonnes per annum with an estimated final discounted price point of £18-£20 per tonne once the high volumes have been achieved

Toyin, sometimes a product is ahead of its time. Now, even though the sugar industry still has politicians in its pocket the awareness of the importance of gut health highlighted by the diabetes and obesity crisis and also scares about the current sweetener alternatives out there, is forcing major suppliers of sugary products such as Coca Cola to reconsider their offerings. Don't forget that since 2020 Opti has been receiving an annual pre-launch royalty fee from its US Partner and DSM/Firmenich are rushing to have their own steviol based sweetbiotix offerings ready for B2B Customer use. There have been a number of false dawns but the latest delay is more likely to do with final regulatory approval rather than an appetite for a major B2B Customer to get it on the shelves.